Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...

Pfizer’s 7%+ yield is tempting, but rising political, regulatory, and business risks threaten its stability and growth ...

Pfizer's reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics (GBT) has been confirmed, with the $68.50-per-share deal valuing GBT at $5.4 billion.

Regardless of which you choose, Pfizer's (NYSE: PFE) share price has declined during the period. Pfizer's dismal stock performance in recent years underscores the challenges the big drugmaker faces.

Pfizer no longer has any SCD treatments on the market after voluntarily stopping Oxbryta sales last fall, citing clinical information that “now indicates the overall benefit of Oxbryta no longer ...

Pfizer has experienced disappointing product and pipeline setbacks as well. It withdrew sickle cell disease therapy Oxbryta from the market last year after concluding that the benefits no longer ...

Pick a time frame -- year to date, last 12 months, last three years, last five years, or last 10 years. Regardless of which you choose, Pfizer's (NYSE: PFE) share price has declined during the period.

Sickle Cell Disease Market Insight, Epidemiology And Market Forecast - 2034The sickle cell disease treatment market is experiencing signific ...

The Sickle Cell Disease Treatment Market is expected to reach at a CAGR of 15.8% during the forecast period 2025-2033. The Sickle Cell Disease Treatment Market is growing due to rising disease ...

The recent formation of the FIBRE Consortium, a collaboration involving Pfizer (NYSE:PFE) and other pharmaceutical partners, aims to pioneer advancements in fibrotic disease management. Alongside ...

Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast of a dominant position in the lucrative oncology space. Oncology or cancer is one of the most sought-after areas in the pharma/biotech ...